The Diagnosis and Prenatal Management of Non-RHD Alloimmunizations.

Authors

Mar Bennasar, Antoni Borrell

Published in

Prenatal diagnosis. Aug 05, 2026. Epub Aug 05, 2026.

Abstract

Red blood cell (RBC) alloimmunization remains a relevant cause of hemolytic disease of the fetus and newborn (HDFN). Although RhD immunization has significantly decreased since the implementation of systematic prophylaxis, it is still the main cause of alloimmunization in pregnancy. Clinically significant non-RhD alloantibodies, particularly those of the Rh (c, C, E), Kell, Kidd, Duffy, and MNS systems, are associated with variable risk of fetal anemia and account for an increasing proportion of alloimmunized pregnancies requiring specialized prenatal care. Most diagnostic algorithms and management protocols are based on evidence derived from RhD alloimmunization. Although these frameworks are often extrapolated to other alloantibodies, important differences exist regarding antibody titration and critical thresholds, the diagnostic accuracy of non-invasive fetal antigen genotyping, and the risk and timing of fetal and neonatal interventions. These differences underscore the need for antibody-specific considerations in the prenatal diagnosis and management of non-RhD alloimmunization. Though advances in non-invasive diagnostic techniques have improved risk stratification and optimized prenatal management, individualized care pathways in alloimmunized pregnancies are needed. This review will focus on the current strategies for prenatal diagnosis and risk assessment in pregnancies complicated by non-RhD red cell alloimmunization.

PMID:
42555973
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.